Journal
ACS NANO
Volume 11, Issue 3, Pages 2397-2402Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b01197
Keywords
-
Categories
Funding
- MINECO [MAT2015-74381-JIN, RYC-2014-16962, CP/11/00273, PI14/ 00554]
- Science Foundation Ireland (SFI) [12/IA/ 1422]
- Conselleria de Cultura, Education e Ordenacion Universitaria (Centro singular de investigation de Galicia accreditation) [ED431G/09]
- European Regional Development Fund (ERDF)
Ask authors/readers for more resources
In this Perspective, we describe current challenges and recent advances in efficient delivery and targeting of nanoparticles in vivo. We discuss cancer therapy, nanoparticle biomolecule interactions, nanoparticle trafficking in cells, and triggers and responses to nanoparticle cell interactions. No matter which functionalization strategy to target cancer is chosen, passive or active targeting, more than 99% of the nanoparticles administered in vivo end up in the mononuclear phagocytic system, mainly sequestered by macrophages. Comprehensive studies, such as the one reported by MacParland et al. in this issue of ACS Nano, will help to close the gap between nanotechnology-based drug-delivery solutions and advanced medicinal products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available